IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes

Inclusion criteria:

Main inclusion criteria:

• Age ≥ 18 years and ≤ 70 years at screening

• Male or female of non-child-bearing potential (meaning for women: not currentlypregnant, post-menopausal female or using condoms and either intrauterine devices or 3-monthly contraceptive injection or birth-control pill.)

Healthy subjects:

• No apparent disease requiring medication

• BMI < 25 kg/ m2

• C-reactive protein ≤ 2 mg/L

Obese diabetic type 2 subjects:

• Type 2 diabetes

• HbA1c 7.0 -10.0%

• BMI ≥ 30.0 kg/m2

• C-reactive protein ≥ 2 mg/L

Exclusion criteria:

Subjects will be excluded from the study if they meet any of the following criteria:

• Mental incapacity, unwillingness or language barriers precluding adequateunderstanding or cooperation

• Aversion or allergy to paracetamol or any component of the meal.

• Known history of allergy or hypersensitivity to any component of the investigationalproduct formulations

• Concomitant treatment with GLP-1 agonists, DPP-4 inhibitors, insulin or insulinderivative

• Change in diabetes medication within the last 30 days

• Any biologic drugs targeting the immune system

• Fever, or other signs of infection requiring antibiotics within 3 weeks prior toscreening, history of recurrent infection, immunodeficiency, known HIV ortuberculosis infection, active foot ulcer

• Participation in another study with investigational drug within 30 days prior toScreening and during the present study

• eGFR < 30 mL/min/1.73m2 per MDRD formula or kidney transplant (regardless of renalfunction)

• Known active or recurrent hepatic disorder (including cirrhosis, hepatitis B andhepatitis C, or confirmed ALAT/ASAT levels > 3 times ULN or total bilirubin > 2times ULN),

• Haemoglobin <10.0 g/dL, white blood cell <3.0 x 103/mm3, platelet count <125 x 103/mm3

• Atrial fibrillation and/or a pacemaker